In-House vs. External Lab Processing: What the Difference Means for Your Cells

When a patient consents to an autologous stem cell procedure, there is an assumption embedded in that consent: that the cells collected from their body will be handled with care, processed under controlled conditions, and delivered back to them in viable, functional form. What many patients do not know is that the path those cells travel between collection and injection varies dramatically depending on the clinic’s processing model.

Some clinics collect, process, and inject all within the same facility on the same day. Others collect cells from patients and then ship them to an external laboratory, where processing occurs hours or a day later, after which the material is returned or the patient comes back on a different visit. These two models are not equivalent, and understanding the difference has real implications for cell quality, transparency, and patient safety.

This article explains how each model works, what happens to cells during transport, where quality control diverges, and what patients can reasonably ask their clinic about before committing to a procedure.

The Two Processing Models in Regenerative Medicine

How External Lab Processing Works

In the external processing model, cells are collected at the clinic, typically through a bone marrow aspiration or adipose tissue harvest procedure. The collected material is then packaged under sterile conditions and transported, usually by a temperature-controlled courier service, to an external processing laboratory that may be located anywhere from a few miles away to across state lines.

At the external facility, trained laboratory staff process the raw material to concentrate the cells of interest, typically mesenchymal stem cells. The processed product is then either shipped back to the clinic or held for the patient’s return visit. The total time between collection and the patient receiving the final injection may span many hours or, in some cases, twenty-four hours or more.

This model is common in clinical practice, particularly among clinics that have not made the infrastructure investment required to operate an on-site laboratory. External processing facilities can handle larger volumes of samples from multiple clinics, which may make them cost-effective for practices that perform lower volumes of regenerative procedures.

How In-House Processing Works

In the in-house model, collection, processing, and injection all occur within the same facility during the same clinical visit. The physician collects the cell material, which is then transferred to an on-site laboratory where trained staff process it using centrifugation and other concentration methods. The physician reviews the quality of the processed product before proceeding with the injection. The patient receives the injection on the same day, typically within a few hours of collection.

This model requires capital investment in laboratory equipment and personnel, as well as the clinical expertise to run a compliant, quality-controlled laboratory environment. It also requires a coordinated workflow between clinical and laboratory staff that must function reliably on procedure days.

The defining feature of in-house processing is the elimination of the transport step and the compression of the timeline from collection to injection into a single controlled session.

What Happens to Cells During Transport

Temperature Sensitivity and Viability Loss

Mesenchymal stem cells are biologically sensitive to conditions outside their normal physiological environment. Optimal cellular function depends on maintaining appropriate temperature, oxygen levels, and pH. When cells are removed from the body and placed in a collection medium, they begin to experience stress from this environmental change immediately.

Published research on cell therapy quality confirms that temperature excursions during handling and transport directly affect cell viability. Cells stored above their optimal temperature range experience accelerated metabolic activity and depletion of energy reserves. Cells exposed to temperatures that are too cold suffer membrane damage. The concept of a validated cold chain, where temperature is continuously monitored and maintained within a defined range throughout transport, exists precisely because deviations from this range can significantly reduce the number of viable cells that arrive at their destination.

Research also highlights a specific challenge with post-thaw viability assessment: cellular injuries from temperature stress may not manifest immediately. Studies have found that a significant proportion of cell death in stressed populations becomes apparent only twenty-four to forty-eight hours after the stress event, meaning that a viability reading taken immediately after transport may overestimate the actual functional cell count. The cells may appear to pass quality checks but have already sustained damage that will reduce their biological activity once injected.

Time Between Collection and Processing

Time is a compounding variable for cell quality. Cells in unprocessed whole tissue or aspirate are viable when collected, but they are also in a sub-optimal environment outside their normal biological context. The longer they remain in this state before being concentrated and processed, the greater the opportunity for cell death and quality degradation.

Processing cells within four to six hours of collection is generally considered favorable from a quality standpoint. A same-day, on-site workflow moves cell material from collection to centrifuge within ninety minutes. A shipped-sample workflow, by contrast, may not begin processing until twelve to twenty or more hours after collection. That gap represents a meaningful difference in the biological condition of the cells at the time of processing.

This does not mean that all external lab processing produces inferior outcomes, or that all in-house processing is automatically superior. Properly validated transport protocols with rigorous cold chain management can reduce transport-related viability loss substantially. But it does mean that time-to-processing is a quality variable that matters, and patients should understand which model their clinic uses.

Quality Control: Where the Models Diverge

Who Is Responsible for Cell Integrity in Each Model

In the external processing model, responsibility for cell integrity is split across two organizations. The clinic is responsible for collection technique, preparation of the sample for transport, and the integrity of the packaging and handoff to the courier. The external laboratory is responsible for receiving the sample in acceptable condition, processing it according to protocol, and producing a quality product.

When something goes wrong, whether due to collection errors, transport problems, or processing deviations, the two entities each have limited visibility into what happened at the other’s facility. Patients who receive lower-than-expected cell counts or poor viability results may find that the clinic and the external lab each point to the other’s portion of the chain as the source of the problem. The patient is left with little recourse and no direct visibility into what happened to their cells during the hours they were out of the clinic’s control.

In the in-house model, there is a single team and a single chain of custody. If a quality problem occurs, it occurred within one controlled environment, and the same physician and staff who collected the cells are responsible for every step up to the injection. This single point of accountability is not just a logistical convenience; it is a structural quality feature.

What Documentation Looks Like in Each Case

A central question for patients is what documentation they receive about the cells that were injected into their body. This is not a trivial question. Knowing the cell count and viability percentage of the material that was delivered is relevant clinical information, both for understanding the likely biological effect and for evaluating the procedure at follow-up.

In the external processing model, the clinic receives a report from the external laboratory, if they request one. The report describes the cell count and viability of the processed product. However, this documentation is generated by the external facility and shared with the clinic as part of their business relationship. It is not typically patient-facing documentation by default, and in many clinics patients never see or receive a copy. There is also a gap between what was processed at the external lab and what was ultimately injected, since transport back to the clinic introduces another opportunity for quality variation.

In the in-house processing model, the report is generated on-site, often on the same day, by the laboratory team that prepared the cells. The physician can review this report before making the decision to proceed with the injection. If cell quality does not meet the clinic’s threshold, the physician can intervene in real time, something that is not possible in an external lab model. Patients in in-house settings can ask to receive a copy of the laboratory report generated on their procedure day.

Why This Matters for the Patient

What You Can Verify vs. What You Have to Trust

The practical consequence of these two models is a difference in what patients can independently verify versus what they must take on trust.

With external processing, patients trust that the external laboratory maintained proper conditions during processing, trust that the clinic requested and received quality documentation, and trust that the documentation reflects the actual quality of what was ultimately injected. At no point in this chain does the patient have direct access to information. They are trusting a multi-organizational process that they have no visibility into.

With in-house processing, patients can ask on the morning of their procedure whether documentation has been generated and can request a copy. They can ask the physician whether the cell count and viability met the clinic’s quality threshold before proceeding. This is not a guarantee of outcome, but it is verifiable information rather than trust.

For a procedure that is paid for out-of-pocket and involves cells collected from the patient’s own body being introduced into a joint or tissue, the ability to verify rather than simply trust is a meaningful quality assurance difference.

Questions to Ask Your Clinic About Their Processing Model

Patients approaching a regenerative medicine consultation should ask these questions before committing to a procedure:

First, ask whether your cells will be processed on-site or sent to an external laboratory. This is a direct question that requires a direct answer. If the answer is external, follow up by asking where the laboratory is located, how long transport typically takes, and what their validated cold chain protocol is.

Second, ask whether you will receive a cell count and viability report before your procedure proceeds. A clinic with in-house processing should be able to answer yes. A clinic using external processing should still be able to provide you with the report they receive from the external lab, even if the timing differs.

Third, ask who runs the laboratory and what credentials they hold. A clinical laboratory handling human cells should be operated by trained laboratory scientists, and the facility should meet applicable regulatory and accreditation standards.

Fourth, ask what happens if the cell quality from your sample falls below acceptable levels on procedure day. Clinics with clear quality standards and in-house visibility can answer this question specifically. They may indicate they would not proceed, would discuss the situation with you, or would explore options for repeating the collection. Clinics with external processing have less ability to intervene in real time.

Fifth, ask whether the laboratory report from your procedure will be added to your medical record and whether you can receive a copy. This documentation belongs to you and should be available for any physician involved in your care going forward.

The answers to these five questions tell you a great deal about a clinic’s commitment to quality, transparency, and patient-centered care, regardless of which processing model they use.

Sources

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.